June 17, 2020 / 3:17 PM / 16 days ago

BRIEF-Ascletis Pharma Says Sagimet Biosciences Announced Positive Results Of ‍Phase 2 NASH Trial​

June 17 (Reuters) - Ascletis Pharma Inc:

* SAGIMET BIOSCIENCES ANNOUNCED POSITIVE RESULTS ON ORAL, ONCE-DAILY NON-ALCOHOLIC STEATOHEPATITIS DRUG CANDIDATE TVB-2640

* BUSINESS PARTNER SAGIMET BIOSCIENCES RESULTS FROM PHASE 2 (FASCINATE-1) CLINICAL TRIAL

* PRELIM DATA SHOWS TVB-2640 SIGNIFICANTLY REDUCED LIVER FAT, PRIMARY EFFICACY ENDPOINT OF THIS TRIAL

* STUDY SHOWS SIGNIFICANT DOSE-DEPENDENT, RELATIVE REDUCTION IN LIVER FAT OF 28.2% IN 50 MG GROUP VERSUS INCREASE OF 4.5% IN PLACEBO GROUP Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below